Neurology

Prediction of Naming Outcome With FMRI Language Lateralization in Left Temporal Epilepsy Surgery.  98:E2337-E2346. 2022

Prognosis After Stroke: Do We Have What We Need to Talk With Patients and Their Families? 2022

Nucleosides Associated With Incident Ischemic Stroke in the REGARDS and JHS Cohorts.  98:E2097-E2107. 2022

Impact of Telestroke Implementation on Emergency Department Transfer Rate.  98:E1617-E1625. 2022

Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study.  98:E376-E389. 2022

Disparities of Care in Post-Concussive Pediatric Patients.  98:S13. 2022

Efficacy of Outpatient Infusion Therapy in Pediatric Patients With Post-Concussive Headaches.  98:S14-S15. 2022

Evaluation of Sports-Related Concussion in Children (5-12) and Adolescents (13-18).  98:S12-S13. 2022

Multiple Sclerosis Diagnostic Criteria: Moving Ahead or Walking in Place?.  98:12-13. 2022

Representation of Women in Stroke Clinical Trials: A Review of 281 Trials Involving More Than 500,000 Participants.  97:e1768-e1774. 2021

Safety and Efficacy of Natalizumab as Adjunctive Therapy for People With Drug-Resistant Epilepsy: A Phase 2 Study.  97:e1757-e1767. 2021

Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.  97:E1560-E1570. 2021

Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum.  97:e1334-e1342. 2021

Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas: Implications for Clinical Trials.  97:S15-S24. 2021

Sex and Race Differences in the Risk of Ischemic Stroke Associated With Fasting Blood Glucose in REGARDS.  97:e684-e694. 2021

Status and Recommendations for Incorporating Biomarkers for Cutaneous Neurofibromas Into Clinical Research.  97:S42-S49. 2021

Silent Myocardial Infarction and Subsequent Ischemic Stroke in the Cardiovascular Health Study.  97:e436-e443. 2021

Neighborhood Socioeconomic Status and Stroke Incidence: A Systematic Review.  96:897-907. 2021

Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration.  96:e2296-e2312. 2021

Repurposing Domperidone in Secondary Progressive Multiple Sclerosis: A Simon 2-Stage Phase 2 Futility Trial.  96:e2313-e2322. 2021

Expanding the Spectrum of Chronic Immune Sensory Polyradiculopathy: CISP-Plus.  96:e2078-e2089. 2021

Association of De Novo RNF213 Variants With Childhood Onset Moyamoya Disease and Diffuse Occlusive Vasculopathy.  96:e1783-e1791. 2021

Prospective Analysis of Leisure-Time Physical Activity in Midlife and Beyond and Brain Damage on MRI in Older Adults.  96:e964-e974. 2021

Dystonia and Tremor: A Cross-Sectional Study of the Dystonia Coalition Cohort.  96:e563-e574. 2021

Paraneoplastic Myeloneuropathies: Clinical, Oncologic, and Serologic Accompaniments.  96:e632-e639. 2021

Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a.  96:e214-e227. 2021

Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis.  96:e111-e120. 2021

Racial Differences in Atrial Cardiopathy Phenotypes in Ischemic Stroke Patients. 2020

Bing-Neel syndrome mimicking a meningioma.  95:838-839. 2020

Pediatric Multiple Sclerosis Severity Score in a large US cohort.  95:e1844-e1853. 2020

Cardiovascular risk factors and accelerated cognitive decline in midlife: The CARDIA Study.  95:e839-e846. 2020

Minimal manifestation status and prednisone withdrawal in the MGTX trial.  95:e755-e766. 2020

Comorbidity is associated with disease activity in MS: Findings from the CombiRx trial.  95:e446-e456. 2020

The CREST-2 experience with the evolving challenges of COVID-19: A clinical trial in a pandemic.  95:29-36. 2020

Revised Self-Monitoring Scale: A potential endpoint for frontotemporal dementia clinical trials.  94:e2384-e2395. 2020

Author response: Dietary patterns during adulthood and cognitive performance in midlife: The CARDIA study.  94:636. 2020

Defining research priorities in dystonia.  94:526-537. 2020

Phrenic neuropathy water immersion dyspnea: Clinical findings and need for patient counseling.  94:e1314-e1319. 2020

Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?.  94:481-494. 2020

Education Research: Multiple sclerosis and neuroimmunology fellowship training status in the United States.  94:495-500. 2020

Child Neurology: Arterial ischemic stroke in a 12-year-old patient with cardiac myxomas.  94:e1103-e1106. 2020

Unraveling the risk factors for spontaneous intracerebral hemorrhage among West Africans.  94:e998-e1012. 2020

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.  93:e1452-e1462. 2019

Child Neurology: Spastic paraparesis and dystonia with a novel ADCY5 mutation.  93:510-514. 2019

Hand stereotypies: Lessons from the Rett Syndrome Natural History Study.  92:E2594-E2603. 2019

Reader response: Alien hand syndrome.  92:1070. 2019

Inflammatory cytokines and ischemic stroke risk: The REGARDS cohort.  92:E2375-E2384. 2019

How should we normalize regional volume abnormalities in childhood neurodegenerative disorders?.  92:779-780. 2019

Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome.  92:E1912-E1925. 2019

A survey of risk tolerance to multiple sclerosis therapies.  92:E1634-E1642. 2019

Dietary patterns during adulthood and cognitive performance in midlife: The CARDIA study.  92:E1589-E1599. 2019

A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS.  92:469-480. 2019

The prevalence of MS in the United States: A population-based estimate using health claims data.  92:E1029-E1040. 2019

Serum magnesium and calcium levels in relation to ischemic stroke: Mendelian randomization study.  92:E944-E950. 2019

Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.  92:329-337. 2019

Reducing neurodisparity: Recommendations of the 2017 AAN Diversity Leadership Program.  92:e274-e280. 2019

Teaching neuroimages: Facial swelling and intracerebral hemorrhage from venous hypertension in a dialysis patient.  92:E521-E522. 2019

Word comprehension in temporal cortex and Wernicke area: A PPA perspective.  92:E224-E233. 2019

Clinical and neural responses to cognitive behavioral therapy for functional tremor.  93:1-12. 2019

PCNT point mutations and familial intracranial Aneurysms.  91:E2170-E2181. 2018

Racial differences in recurrent ischemic stroke risk and recurrent stroke case fatality.  91:E1741-E1750. 2018

Sleep duration and risk of incident stroke by age, sex, and race the REGARDS study.  91:E1702-E1709. 2018

Outcomes after carotid endarterectomy among elderly dual Medicare-Medicaid-eligible patients.  91:E1553-E1558. 2018

Clinical trial design for cutaneous neurofibromas.  91:S31-S37. 2018

Cutaneous neurofibromas: Current clinical and pathologic issues.  91:S5-S13. 2018

New diagnosis of cancer and the risk of subsequent cerebrovascular events.  90:E2025-E2033. 2018

Cerebellar volume as an imaging marker of development in infants with tuberous sclerosis complex..  90:e1493-e1500. 2018

Diet quality is associated with disability and symptom severity in multiple sclerosis.  90:E1-E11. 2018

MicroRNAs in CSF as prodromal biomarkers for Huntington disease in the PREDICT-HD study.  90:E264-E272. 2018

Cognitive trajectories over 4 years among HIV-infected women with optimal viral suppression.  89:1594-1603. 2017

Cognitive trajectories over 4 years among HIV-infected women with optimal viral suppression.  89:1594-1603. 2017

Author response: High hypothetical interest in physician-assisted death in multiple sclerosis.  89:1429-1430. 2017

Child Neurology: Childhood basilar artery occlusion and stroke.  89:e68-e70. 2017

Author response: Practice guideline summary: Use of fMRI in the presurgical evaluation of patients with epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.  89:640-641. 2017

Permanent CSF shunting after intraventricular hemorrhage in the CLEAR III trial.  89:355-362. 2017

Body mass index and outcome after revascularization for symptomatic carotid artery stenosis.  88:2052-2060. 2017

Child Neurology: LAMA2 muscular dystrophy without contractures.  88:e199-e203. 2017

Effect of a long-term intensive lifestyle intervention on prevalence of cognitive impairment.  88:2026-2035. 2017

Clinical Reasoning: A 45-year-old man with weakness and myalgia after orthopedic surgery.  88:e185-e189. 2017

Racial differences in statin adherence following hospital discharge for ischemic stroke.  88:1839-1848. 2017

Evidence for a causal relationship between low Vitamin D, high BMI, and pediatric-onset MS.  88:1623-1629. 2017

High hypothetical interest in physician-assisted death in multiple sclerosis.  88:1528-1534. 2017

Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification.  88:1197-1205. 2017

Child Neurology: Rocky Mountain spotted fever encephalitis.  88:e92-e95. 2017

Long-term functional outcome in patients with acquired infections after acute spinal cord injury.  88:892-900. 2017

Practice guideline summary: Use of fMRI in the presurgical evaluation of patients with epilepsy.  88:395-402. 2017

A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.  88:152-159. 2017

Neonatal seizures in premature infants with IVH: are myoclonic jerks seizures?.  88:92-95. 2017

Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1.  87:2575-2584. 2016

Effect of aphasia on acute stroke outcomes.  87:2348-2354. 2016

Neighborhood socioeconomic index and stroke incidence in a national cohort of blacks and whites.  87:2340-2347. 2016

Twelve-month recovery of medical decision-making capacity following traumatic brain injury.  87:1052-1059. 2016

Pediatric multiple sclerosis Clinical features and outcome.  87:S74-S81. 2016

Symptom profiles of autism spectrum disorder in tuberous sclerosis complex.  87:766-772. 2016

Current status and recommendations for biomarkers and biobanking in neurofibromatosis.  87:S40-S48. 2016

Type 2 diabetes mellitus is associated with brain atrophy and hypometabolism in the ADNI cohort.  87:595-600. 2016

Health insurance affects the use of disease-modifying therapy in multiple sclerosis.  87:365-374. 2016

Recommendations for observational studies of comorbidity in multiple sclerosis..  86:1446-1453. 2016

The challenge of comorbidity in clinical trials for multiple sclerosis..  86:1437-1445. 2016

Hostile attitudes and effortful coping in young adulthood predict cognition 25 years later.  86:1227-1234. 2016

Differences in the role of black race and stroke risk factors for first vs recurrent stroke.  86:637-642. 2016

Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report.  86:245-252. 2016

New-onset refractory status epilepticus.  85:1604-1613. 2015

Author response.  85:742-743. 2015

Emerging Subspecialties in Neurology: Neurorehabilitation.  85:e50-e52. 2015

DNA methylation slows effects of C9orf72 mutations.  84:1616-1617. 2015

Ictal adipokines are associated with pain severity and treatment response in episodic migraine.  84:1409-1418. 2015

Marijuana Usage and Disability in MS in the NARCOMS Registry.  April 06, 2015; 84 (14 Supplement):P1.140-P1.140. 2015

Long-term impact of stroke on family caregiver well-being: A population-based case-control study.  84:1323-1329. 2015

Differences in Alzheimer disease clinical trial outcomes based on age of the participants.  84:1121-1127. 2015

Placebo effect of medication cost in Parkinson disease: A randomized double-blind study.  84:794-802. 2015

Quality improvement in neurology: primary headache quality measures..  84:200-203. 2015

Global investigation and meta-analysis of the C9orf72 (G4C2)n repeat in Parkinson disease..  83:1906-1913. 2014

Clinical response to Bevacizumab in schwannomatosis.  83:1986-1987. 2014

Protective environmental factors for neuromyelitis optica.  83:1923-1929. 2014

ABO blood type, factor VIII, and incident cognitive impairment in the REGARDS cohort.  83:1271-1276. 2014

JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene..  83:727-732. 2014

Defining the clinical course of multiple sclerosis: The 2013 revisions.  83:278-286. 2014

Spectrogram screening of adult EEGs is sensitive and efficient.  83:56-64. 2014

Paroxysmal hypnogenic dyskinesia.  82:1935. 2014

Feasibility of Huntington disease trials in the disease prodrome.  82:824-825. 2014

Randomized Evaluation of Carotid Occlusion and Neurocognition (RECON) trial.  82:744-751. 2014

Mortality in patients with multiple sclerosis.  81:184-192. 2013

Report of stroke-like symptoms predicts incident cognitive impairment in a stroke-free cohort.  81:113-118. 2013

Management of carotid stenosis in women consensus document.  80:2258-2268. 2013

Cerebral hemodynamics and cognitive decline: Swimming against the current.  80:2086-2087. 2013

Pearls and Oy-sters: Acute ischemic stroke caused by atypical thrombotic thrombocytopenic purpura.  80. 2013

Clinicopathologic variability of the GRN A9D mutation, including amyotrophic lateral sclerosis.  80:1771-1777. 2013

Adherence to a Mediterranean diet and risk of incident cognitive impairment.  80:1684-1692. 2013

Effect of duration and age at exposure to the Stroke Belt on incident stroke in adulthood.  80:1655-1661. 2013

Disability in multiple sclerosis: A reference for patients and clinicians.  80:1018-1024. 2013

Functional impairment in progressive supranuclear palsy.  80:380-384. 2013

Recommendations for imaging tumor response in neurofibromatosis clinical trials..  81. 2013

Assessment of cortical and striatal involvement in 523 Huntington disease brains.  79:1708-1715. 2012

Growth failure and outcome in Rett syndrome: Specific growth references.  79:1653-1661. 2012

Racial differences in albuminuria, kidney function, and risk of stroke.  79:1686-1692. 2012

What is it about neighborhood characteristics that influence survival after a stroke or TIA?.  79:1190-1191. 2012

Prevalence and significance of stroke symptoms among patients receiving maintenance dialysis.  79:981-987. 2012

Novel late-onset Alzheimer disease loci variants associate with brain gene expression..  79:221-228. 2012

Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study).  79:163-169. 2012

Treatment consent capacity in patients with traumatic brain injury across a range of injury severity.  78:1472-1478. 2012

Cognitive performance of GBA mutation carriers with early-onset PD The CORE-PD study.  78:1434-1440. 2012

Survival in MS A randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.  78:1315-1322. 2012

CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion.  78:690-695. 2012

Incidence and prevalence of epilepsy among older US Medicare beneficiaries.  78:448-453. 2012

Carotid stenosis: To revascularize, or not to revascularize: That is the question.  78:294. 2012

Carotid stenosis: to revascularize, or not to revascularize: that is the question..  78:294. 2012

Cerebral hemodynamics and cognitive impairment: Baseline data from the RECON trial.  78:250-255. 2012

Evaluation of safety monitoring guidelines based on MRI lesion activity in multiple sclerosis.  77:2089-2096. 2011

Reply from the authors.  77. 2011

Clinical severity and quality of life in children and adolescents with Rett syndrome.  77:1812-1818. 2011

Quantifying physical decline in juvenile neuronal ceroid lipofuscinosis (Batten disease).  77:1801-1807. 2011

Vascular risk factors and cognitive impairment in a stroke-free cohort.  77:1729-1736. 2011

To the editor.  77. 2011

A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS..  77:1551-1560. 2011

GFAP mutations, age at onset, and clinical subtypes in Alexander disease.  77:1287-1294. 2011

Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS.  77:138-144. 2011

Common viruses associated with lower pediatric multiple sclerosis risk.  76:1989-1995. 2011

Behavioral therapy to treat urinary incontinence in Parkinson disease.  76:1631-1634. 2011

Interferon β-1b and glatiramer acetate effects on permanent black hole evolution.  76:1222-1228. 2011

NMO Spectrum Disorder in Children and Adolescents.  76:A395-A396. 2011

Pituitary Adenoma Complicated By Multifocal Fibrosclerosis Involving Sella and Retroperitoneum.  76:A250-A251. 2011

Recurrent Demyelinating Events Following Pediatric Optic Neuritis (pON).  76:A394-A394. 2011

Racial and geographic differences in fish consumption: The regards study.  76:154-158. 2011

Neurocognitive sequelae in African American and Caucasian children with multiple sclerosis.  75:2097-2102. 2010

Association of reversed Robin Hood syndrome with risk of stroke recurrence.  75:2003-2008. 2010

A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2.  75:1189-1194. 2010

A case of neurosarcoidosis successfully treated with rituximab.  75:568-570. 2010

Reply from the authors.  74:1554-1555. 2010

Epilepsy and the natural history of Rett syndrome.  74:909-912. 2010

25-Hydroxyvitamin D levels and cognitive performance and decline in elderly men.  74:33-41. 2010

Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis.  74:1041-1047. 2010

Younger children with MS have a distinct CSF inflammatory profile at disease onset.  74:399-405. 2010

Association of higher diastolic blood pressure levels with cognitive impairment.  73:589-595. 2009

Reply from the authors.  73:571. 2009

Dietary intake in adults at risk for Huntington disease: Analysis of PHAROS Research Participants.  73:385-392. 2009

Subthalamic nucleus and its connections: Anatomic substrate for the network effects of deep brain stimulation.  72:1110. 2009

Depression in Pediatric MS Patients Correlates with Increased Disease Severity and Selective Neuropsychological Deficits.  72:A371-A372. 2009

Hepatitis vaccines and pediatric multiple sclerosis: Does timing or type matter?.  72:870-871. 2009

Personality and lifestyle in relation to dementia incidence.  72:253-259. 2009

Comorbidity delays diagnosis and increases disability at diagnosis in MS.  72:117-124. 2009

A cross-sectional study of bone health in multiple sclerosis.  73:1394-1398. 2009

Declining financial capacity in mild cognitive impairment: A 1-year longitudinal study.  73:928-934. 2009

Declining financial capacity in patients with MCI: A one-year longitudinal study.  73:928-934. 2009

Editorial: Relapses in multiple sclerosis: Important or not?.  73:1612-1613. 2009

Medical decision-making capacity in patients with malignant glioma.  73:2086-2092. 2009

Optic neuropathy in patients with glioblastoma receiving bevacizumab.  73:1924-1926. 2009

Invited Article: The US health care system: Part 1: Our current system.  71:1907-1913. 2008

Invited article: The US health care system: Part 2: Proposals for improvement and comparison to other systems.  71:1914-1920. 2008

Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis: Reply.  71:1747-1748. 2008

A novel PRNP-P105S mutation associated with atypical prion disease and a rare PrPSc conformation.  71:1431-1438. 2008

CNS aquaporin-4 autoimmunity in children.  71:93-100. 2008

Haplotypes and gene expression implicate the MAPT region for Parkinson disease: The GenePD Study.  71:28-34. 2008

Ethics of placebo-controlled clinical trials in multiple sclerosis: A reassessment.  70:1134-1140. 2008

Investigating genotype-phenotype relationships in Rett syndrome using an international data set.  70:868-875. 2008

Responsiveness and predictive values in PPMS: An uncertain message.  70:1061-1062. 2008

Specific mutations in Methyl-CpG-Binding Protein 2 confer different severity in Rett syndrome.  70:1313-1321. 2008

Study of a Swiss dopa-responsive dystonia family with a deletion in GCH1: Redefining DYT14 as DYT5.  70:1377-1383. 2008

Erratum: Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease (Neurology (2007) 68, (272-276)).  69:617. 2007

Rasmussen syndrome and CNS granulomatous disease with NOD2/CARD15 mutations.  69:640-643. 2007

Higher IgG index found in African Americans versus Caucasians with multiple sclerosis.  69:68-72. 2007

MR tractography depicting damage to the arcuate fasciculus in a patient with conduction aphasia [6].  69:321. 2007

Disparities in the management of multiple sclerosis-related bladder symptoms.  68:1971-1978. 2007

Migraine and retinal microvascular abnormalities: The Atherosclerosis Risk in Communities Study.  68:1694-1700. 2007

Predictors of diagnosis in Huntington disease.  68:1710-1717. 2007

Nothing out of sequence? Think deletion!.  68:975-976. 2007

Reply from the authors [8].  68:965. 2007

NF1 plexiform neurofibroma growth rate by volumetric MRI: Relationship to age and body weight.  68:643-647. 2007

A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease.  68:20-28. 2007

Acute disseminated encephalomyelitis.  68. 2007

Clinical features of children and adolescents with multiple sclerosis.  68. 2007

Hippocampal 1H-MRSI correlates with severity of depression symptoms in temporal lobe epilepsy.  68:364-368. 2007

MRI features of pediatric multiple sclerosis.  68. 2007

Optical coherence tomography and disease subtype in multiple sclerosis.  69:2085-2092. 2007

Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease.  68:272-276. 2007

Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease (Neurolgy (2007) 68, (272-276)).  69:2187. 2007

Relation of vision to global and regional brain MRI in multiple sclerosis.  69:2128-2135. 2007

Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis.  69:1603-1609. 2007

Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: The GenePD study.  67:2206-2210. 2006

Improving caregiver well-being delays nursing home placement of patients with Alzheimer disease.  67:1592-1599. 2006

The Motor Activity Log-28: Assessing daily use of the hemiparetic arm after stroke.  67:1189-1194. 2006

Early progressive encephalopathy in boys and MECP2 mutations.  67:164-166. 2006

Quality improvement in acute stroke: The New York State Stroke Center Designation Project.  67:88-93. 2006

Elevated troponin levels are associated with higher mortality following intracerebral hemorrhage.  66:1330-1334. 2006

Does multiple sclerosis-associated disability differ between races?.  66:1235-1240. 2006

Futility studies: Spending a little to save a lot.  66:626-627. 2006

Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis [3].  66:954. 2006

A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.  66:664-671. 2006

Elevated CSF free kappa light chains correlate with disability prognosis in multiple sclerosis.  67:1288-1290. 2006

Perception of motor strength and stimulus magnitude are correlated in stroke patients.  66:1444-1446. 2006

BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study.  65:1823-1825. 2005

Occupation and parkinsonism in three movement disorders clinics.  65:1430-1435. 2005

Changes in the ascertainment of multiple sclerosis.  65:1066-1070. 2005

MRI as a marker for disease heterogeneity in multiple sclerosis.  65:1071-1076. 2005

Frontotemporal dementia progresses to death faster than Alzheimer disease.  65:719-725. 2005

Does gender parity exist in Fabry disease?.  65:508-509. 2005

Blood harmane concentrations and dietary protein consumption in essential tremor.  65:391-396. 2005

Efficacy of rapid IV administration of valproic acid for status epilepticus [3] (multiple letters).  65:500-501. 2005

Medical decision-making in neurodegenerative disease: Mild AD and PD with cognitive impairment.  65:483-485. 2005

A clinical rating scale for Batten disease: Reliable and relevant for clinical trials.  65:275-279. 2005

Spinal fluid 5-methyltetrahydrofolate levels are normal in Rett syndrome.  64:2151-2152. 2005

Headache, cerebrovascular symptoms, and stroke: The atherosclerosis risk in communities study.  64:1573-1577. 2005

Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.  64:992-995. 2005

Unilateral cerebral peduncular atrophy progresses for decades after stroke.  64:A110-A110. 2005

Efficacy of rapid IV administration of valproic acid for status epilepticus.  64:353-355. 2005

Training, competency, and credentialing standards for diagnostic cervicocerebral angiography, carotid stenting, and cerebrovascular intervention: a joint statement from the American Academy of Neurology, the American Association of Neurological Surgeons, the American Society of Interventional and Therapeutic Neuroradiology, the American Society of Neuroradiology, the Congress of Neurological Surgeons, the AANS/CNS Cerebrovascular Section, and the Society of Interventional Radiology..  64:190-198. 2005

Training, competency, and credentialing standards for diagnostic cervicocerebral angiograpny, carotid stenting, and cerebrovascular intervention: A Joint Statement from the American Academy of Neurology, the American Association of Neurological Surgeons, the American Society of Interventional and Therapeutic Neuroradiology, and the Society of Interventional Radiology.  64:190-198. 2005

Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders.  65:1941-1949. 2005

Intracranial arterial dolichoectasia is associated with enlarged descending thoracic aorta [1] (multiple letters).  65:1681-1682. 2005

Multifocal motor sensory demyelinating neuropathy: Inflammatory demyelinating polyradiculoneuropathy.  65:1639-1642. 2005

Pacemaker-induced tachycardia caused by inappropriate response to parkinsonian tremor.  65:1676-1677. 2005

Migraine and other headaches: Associations with Rose angina and coronary heart disease.  63:2233-2239. 2004

Cortical reorganization in malformations of cortical development: A magnetoencephalographic study.  63:1818-1824. 2004

The evolving role of monoamine oxidase inhibitors in the treatment of Parkinson's disease.  63. 2004

Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease.  63:436-442. 2004

Disorganized search on cancellation is not a consequence of neglect.  63:78-84. 2004

Eclampsia, hippocampal sclerosis, and temporal lobe epilepsy: Accident or association?.  62:1352-1356. 2004

Ophthalmologic features of Parkinson's disease.  62:177-180. 2004

Frequency of epilepsy in patients with psychogenic seizures monitored by video-EEG.  61:1791-1792. 2003

A haplotype at the PARK3 locus influences onset age for Parkinson's disease: The GenePD study.  61:1557-1561. 2003

Adenosine A2A receptor modulation of motor systems for symptomatic therapy in Parkinson's disease..  61:S30-S31. 2003

Effect of relapses on development of residual deficit in multiple sclerosis.  61:1528-1532. 2003

II: A2A receptor modulation for symptomatic therapy in Parkinson's disease: Adenosine A2A receptor modulation of motor systems in PD.  61. 2003

Subacute inflammatory demyelinating polyneuropathy.  61:1507-1512. 2003

Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite.  61:1367-1373. 2003

Teddy bears: An observational finding in patients with non-epileptic events.  61:714-715. 2003

A randomized controlled study of the acute and chronic effects of cooling therapy for MS..  60:1955-1960. 2003

Neurotoxicity following addition of intravenous valproate to lamotrigine therapy.  60:1991-1992. 2003

A note of caution on correlation between sibling pairs [6] (multiple letters).  60:1561. 2003

Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease.  60:1189-1191. 2003

Predictors of nursing home placement in Huntington disease.  60:998-1001. 2003

Tic reduction with pergolide in a randomized controlled trial in children.  60:606-611. 2003

Tic reduction in Tourette Syndrome: improvement with pergolide in a randomized controlled trial in children.  60:606-611. 2003

Eight-year follow-up study of brain atrophy in patients with MS.  59:1412-1420. 2002

Weight loss in early stage of Huntington's disease.  59:1325-1330. 2002

Benefit of interferon β-1a on MSFC progression in secondary progressive MS.  59:679-687. 2002

Clinical and genetic heterogeneity in benign hereditary chorea.  59:579-584. 2002

Dopamine transmission in DYT1 dystonia: A biochemical and autoradiographical study.  59:445-448. 2002

Language lateralization in left-handed and ambidextrous people: fMRI data.  59:238-244. 2002

Molecular findings in symptomatic and pre-symptomatic Alexander disease patients.  58:1494-1500. 2002

Plexiform neurofibromas in NF1: Toward biologic-based therapy.  58:1461-1470. 2002

Porphyria presenting with bilateral radial motor neuropathy: Evidence of a novel gene mutation.  58:1118-1121. 2002

HLA-A2 homozygosity but not heterozygosity is associated with Alzheimer disease.  58:973-975. 2002

Depression associated with Parkinson's disease: Clinical features and treatment.  58. 2002

Treatment of ADHD in children with tics: A randomized controlled trial.  58:527-536. 2002

Insomnia associated with thalamic involvement in E200K Creutzfeldt-Jakob disease.  58:362-367. 2002

Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults.  58:368-372. 2002

Epidemiologic study of 203 sibling pairs with Parkinson's disease: The GenePD study.  58:79-84. 2002

Genome-wide scan for Parkinson's disease: The GenePD study.  57:1124-1126. 2001

Bilateral hippocampal atrophy: Consequences to verbal memory following temporal lobectomy.  57:597-604. 2001

Chromosome 22q and the mind-brain interface: Bedside to bench to bedside.  57:377-378. 2001

Large-fiber neuropathy in distal sensory neuropathy with normal routine nerve conduction.  56:1570-1572. 2001

Parkinson's disease, CYP2D6 polymorphism, and age.  56:1363-1370. 2001

Use of the multiple sclerosis functional composite to predict disability in relapsing MS.  56:1324-1330. 2001

Left vagus nerve stimulation suppresses experimentally induced pain [3] (multiple letters).  56:985-986. 2001

Chronic thalamic stimulation for treatment of dystonic paroxysmal nonkinesigenic dyskinesia.  56:268-270. 2001

Postictal stability of proton magnetic resonance spectroscopy imaging (¹H-MRSI) ratios in temporal lobe epilepsy.  56:251-253. 2001

Cardiovascular risk factors and cognitive decline in middle-aged adults.  56:42-48. 2001

Competency to consent to medical treatment in cognitively impaired patients with Parkinson's disease.  56:17-24. 2001

Sensory Guillain-Barré syndrome.  56:82-86. 2001

An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines.  56. 2001

Four-year incidence of psychogenic nonepileptic seizures in adults in Hamilton County, OH.  55:1561-1563. 2000

Pelizaeus-Merzbacher disease: Splice sites are nice sites for disease expression.  55:1072-1073. 2000

The experience of Wernicke's aphasia.  55:1222-1224. 2000

Low mini-mental status predicts mortality in asymptomatic carotid arterial stenosis.  55:30-34. 2000

Low mini-mental status predicts mortality in asymptomatic carotid arterial stenosis. Asymptomatic Carotid Atherosclerosis Study investigators..  55:30-34. 2000

Visual attention impairments in Alzheimer's disease.  54:1954-1959. 2000

Pure topographic disorientation: A distinctive syndrome with varied localization.  54:1864-1866. 2000

Enlarged parietal foramina: Association with cerebral venous and cortical anomalies.  54:1175-1178. 2000

Intrarater and interrater reliability of the MS functional composite outcome measure.  54:802-806. 2000

A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.  54:603-607. 2000

Arm levitation in progressive supranuclear palsy..  54:774. 2000

Rate of functional decline in Huntington's disease.  54:452-458. 2000

Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults [2] (multiple letters).  54:270-272. 2000

Pure topographic disorientation: A distinctive syndrome with varied localization.  54:575-578. 2000

Cognitive correlates of ¹H MRSI-detected hippocampal abnormalities in temporal lobe epilepsy.  53:2052-2058. 1999

Error behaviors associated with loss of competency in Alzheimer's disease.  53:1983-1992. 1999

Visual dysfunction in patients receiving vigabatrin: Clinical and electrophysiologic findings.  53:2082-2087. 1999

Eliminating institutional child abuse: A road too well traveled.  53:1617-1621. 1999

Juvenile Parkinson's disease with REM sleep behavior disorder, sleepiness, and daytime REM onset.  53:1868-1870. 1999

Neurologic complications of pediatric lung transplantation.  53:1542-1549. 1999

Subjective versus objective memory change after temporal lobe epilepsy surgery.  53:1511-1517. 1999

Evidence for the GluR6 gene associated with younger onset age of Huntington's disease.  53:1330-1332. 1999

Clinical and laboratory features of primary progressive and secondary progressive MS.  53:765-771. 1999

Cognitive consequences of coexisting temporal lobe developmental malformations and hippocampal sclerosis.  53:709-715. 1999

Patient-oriented outcome assessment after temporal lobectomy for refractory epilepsy.  53:687-694. 1999

Predictive value of ¹H MRSI for outcome in temporal lobectomy.  53:694-698. 1999

Quantitative MRI in temporal lobe epilepsy: Evidence for fornix atrophy.  53:496-501. 1999

Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults.  52:321-327. 1999

Temporal lobe developmental malformations and hippocampal sclerosis epilepsy surgical outcome.  52:479-484. 1999

Temporal lobe developmental malformations and hippocampal sclerosis: Epilepsy surgery outcome.  53:694-698. 1999

Lesion laterality, neglect, and anosognosia..  51:920-921. 1998

¹H NMR spectroscopy studies of Huntington's disease. Correlations with CAG repeat numbers.  50:1357-1365. 1998

A cross-reactive anti-myelin basic protein idiotope in cerebrospinal fluid cells in multiple sclerosis.  50:411-417. 1998

Age-related changes in the level of urinary myelin basic protein-like material during childhood.  51:1339-1341. 1998

Central poststroke pain and Wallenberg's lateral medullary infarction.  50:1521. 1998

Central poststroke pain associated with lateral medullary infarction.  50:837. 1998

Could pure alexia be due to a disconnection syndrome?.  50:835. 1998

Topiramate increases brain GABA in healthy adults.  51:627-629. 1998

Topiramate increases cerebral GABA in healthy humans.  51:627-629. 1998

Clearing up misunderstandings about clinical trial methodology: a reply to Barnett et al.'s commentary on the ACAS Trial. ACAS Executive Committee, ACAS Data and Safety Monitoring Committee..  48:1743-1745. 1997

Differential diagnosis of Alzheimer's disease.  48. 1997

Anterior translocation of language in patients with left cerebral arteriovenous malformation.  49:802-808. 1997

Central poststroke pain and Wallenberg's lateral medullary infarction: Frequency, character, and determinants in 63 patients.  49:120-125. 1997

Chromosome 17 and hereditary dementia: Linkage studies in three non- Alzheimer families and kindreds with late-onset FAD.  48:949-954. 1997

Clearing up misunderstandings about clinical trial methodology: A reply to Barnett et al.'s commentary on the ACAS trial [2] (multiple letters).  48:1743-1748. 1997

Congenital porencephaly and hippocampal sclerosis: Clinical features and epileptic spectrum.  49:1382-1388. 1997

Corticobasal degeneration: Neuropathologic and clinical heterogeneity.  48:959-969. 1997

Epilepsy surgery outcome: Comprehensive assessment in children.  48:1368-1374. 1997

Evidence for association of HLA-A2 allele with onset age of Alzheimer's disease.  49:512-518. 1997

Hemianopic anosognosia.  49:88-97. 1997

Krabbe continuum or clinical conundrum?.  49:1203-1204. 1997

Oral phenylalanine loading in dopa-responsive dystonia: A possible diagnostic test.  48:1290-1297. 1997

The role of dopamine agonists in early Parkinson's disease.  49. 1997

Validation of the ACAS TIA/stroke algorithm.  48:346-351. 1997

Apolipoprotein E ∈4 association with dementia in a population-based study: The Framingham Study.  46:673-677. 1996

Increased risk of familial late-onset Alzheimer's disease in women.  46:126-129. 1996

Mutation of the prion protein gene at codon 208 in familial Creutzfeldt- Jakob disease.  47:1305-1312. 1996

Positive spontaneous visual phenomena limited to the hemianopic field in lesions of central visual pathways.  47:408-417. 1996

Reply from the Author: Gender and AD.  47:1358. 1996

Sorivudine: a promising drug for the treatment of varicella-zoster virus infection..  45:S73-S75. 1995

Circulating adhesion molecules and inflammatory mediators in demyelination: A review.  45:S22-S32. 1995

Cytokine localization in multiple sclerosis lesions: Correlation with adhesion molecule expression and reactive nitrogen species.  45:S16-S21. 1995

Familial progressive subcortical gliosis: Presence of prions and linkage to chromosome 17.  45:1062-1067. 1995

Genetic anticipation in parkinson's disease.  45:135-138. 1995

Inhibitory cytokines and cytokine inhibitors.  45:S39-S43. 1995

No evidence for association of familial parkinson's disease with cag repeat expansion.  45:1760-1763. 1995

Sorivudine: A promising drug for the treatment of varicella-zoster virus infection.  45:S73-S75. 1995

VISUAL PHENOMENA LIMITED TO THE HEMIANOPIC FIELD IN LESIONS OF THE CENTRAL VISUAL PATHWAYS.  44:A266-A266. 1994

A clinical genetic study of parkinson’s disease: Evidence for dominant transmission.  44:499-506. 1994

Progressive supranuclear palsy: Neuropathologic and clinical heterogeneity.  44:1015-1024. 1994

Capsular genu syndrome [7].  43:1862-1863. 1993

Chiari headaches.  43:1272. 1993

Evidence for neuronal degeneration and dendritic plasticity in cortical pyramidal neurons of huntington's disease: A quantitative golgi study.  43:2088-2096. 1993

Extrapersonal neglect [2].  43:1859-1860. 1993

Nonoptic aphasia: Aphasia with preserved confrontation naming in alzheimer's disease.  43:1900-1907. 1993

Left hemiparalexia..  42:562-569. 1992

A syndrome of autosomal dominant alternating hemiplegia: Clinical presentation mimicking intractable epilepsy; chromosomal studies; and physiologic investigations.  42:2251-2257. 1992

Confusion and memory loss from capsular genu infarction: A thalamocortical disconnection syndrome?.  42:1966-1979. 1992

Kynurenine pathway abnormalities in Parkinson's disease.  42:1702-1706. 1992

Left hemiparalexia.  42:562-569. 1992

Subacute necrotizing encephalopathy: Oxidative phosphorylation defects and the ATPase 6 point mutation.  42:2168-2174. 1992

MRI reveals multiple reversible cerebral lesions in an attack of acute intermittent porphyria..  41:1300-1302. 1991

Clozapine is beneficial for psychosis in parkinson's disease.  41:1699-1700. 1991

Electrophysiologic analysis of early Parkinson’s disease.  41:44-48. 1991

HLA-A2, or a closely linked gene, confers susceptibility to early-onset sporadic alzheimer’s disease in mene.  41:1544-1548. 1991

Morphometric analysis of the prefrontal cortex in huntington’s disease.  41:1117-1123. 1991

Sagittal sinus thrombosis and leptomeningeal medulloblastoma.  41:455-456. 1991

United parkinson foundation neurotransplantation registry on adrenal medullary transplants: Presurgical, and 1– and 2–year follow–up.  41:1719-1722. 1991

Progressive aphasia: A precursor of global dementia? 1990

Bodily neglect and orientational biases in unilateral neglect syndrome and normal subjects.  40:640-643. 1990

Extrapyramidal involvement in Rett’s syndrome.  40:293-295. 1990

Multiple sclerosis sibling pairs: Clustered onset and familial predisposition.  40:1546-1552. 1990

Phenotypic heterogeneity of spinal muscular atrophy mapping to chromosome 5q11.2-13.3 (SMA 5q).  40:1831-1836. 1990

The intracarotid amobarbital procedure as a predictor of memory failure following unilateral temporal lobectomy.  40:605-610. 1990

Transmission and age-at-onset patterns in familial alzheimer’s disease: Evidence for heterogeneity.  40:395-403. 1990

Changes in survival after transient ischemic attacks: Observations comparing the 1970s and 1980s.  39:982-985. 1989

Criteria for termination of phase II chemotherapy for patients with progressive or recurrent brain tumor.  39:62-66. 1989

Ocular stroke and carotid artery dissection.  39:1462-1464. 1989

Phenotypic variation in 2 huntington’s disease families with linkage to chromosome 4.  39:1332-1336. 1989

Reply from the authors: Hemispatial neglect.  39:458. 1989

Reply from the authors: Hemispatial neglect.  39:1006. 1989

Seizures after primary intracerebral hemorrhage.  39:1089-1093. 1989

Clinical and neuropathologic assessment of severity in huntington’s disease.  38:341-347. 1988

Dopaminergic effects on simple and choice reaction time performance in Parkinson’s disease.  38:249-254. 1988

Hemispatial neglect affected by non-neglected stimuli.  38:1207-1211. 1988

Perseveration in behavioral neurology 1987

Aneurysmal compression of the anterior visual pathways.  36:1035-1041. 1986

Krabbe disease: Specific MRI and CT findings.  36:111-115. 1986

Dorsal midbrain syndrome in multiple sclerosis.  31:196-198. 1981

Transient ischemic attacks: A prospective study of 225 patients.  28:746-753. 1978

Metachromatic leukodystrophy: Comparison of early-and late-onset forms.  27:933-941. 1977

Metrizamide encephalography: The use of a new, CSF soluble contrast agent.  27:388. 1977

Stroke in a 15-year-old girl secondary to terminal carotid dissection.  25:725-729. 1975

Subarachnoid hemorrhage caused by rupture of a small superficial artery.  24:319-321. 1974

Neoplasms of the central nervous system: Epidemiologic considerations.  22:40-48. 1972

Peripheral nerve glycolipids in metachromatic leukodystrophy.  17:1033-1033. 1967

Steroid suppression of meningeal inflammation caused by pantopaque.  9:48-52. 1959